MRI and Stable Isotope Tracer Studies for Detecting the Progression of Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Fatty Liver Disease Clinical Trial

— MRI-Detect  

Official title:

MRI and Stable Isotope Tracer Studies for Detecting the Progression of Non-Alcoholic Steatohepatitis (NASH)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04227782
• Other study ID #: MRI-DETECT
• Status: Active, not recruiting
• Start date: March 1, 2020
• Est. completion date: October 1, 2027

Study information

• Verified date: November 2023
• Source: University of Oxford
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

One-third of the world's population suffers from Non-Alcoholic Fatty Liver Disease (NAFLD), that is a disease with an accumulation of fat in the liver. Some patients with NAFLD will progress in their disease to develop inflammation, scarring of the liver tissue, and cirrhosis that can lead to liver failure. The mechanisms of the disease and its progression are still not fully understood. It is therefore critical to find early markers that can identify the patients that will progress so that they can be treated early. A compound called L-carnitine, synthesised in the body from two amino acids; lysine and methionine, is critical for fat metabolism. Some studies have shown that it is decreased in liver disease patients and that L-carnitine supplementation can protect the liver function. This study aims to increase the understanding of the mechanisms behind NAFLD disease progression through its different stages. This may help diagnostic methods to be developed to predict the patients at risk for developing severe liver disease. Furthermore, fat metabolism and L-carnitine levels will be established in the different disease stages to evaluate whether fat metabolism could be compromised. Magnetic Resonance Imaging (MRI) will be used for imaging of the whole liver and the heart to investigate metabolism and function non-invasively. Whole-body metabolism and how carbohydrates are taken up from diets are converted to fats in the body will be explored using stable isotope labelling. This study will recruit 30 participants with NAFLD; 10 each for low-risk NALFD, biopsy-proven NASH and compensated NASH cirrhosis. Participants will undergo MRI, followed by a stable isotope labelled study, where through blood- and breathe samples, metabolism will be investigated. An additional 10 healthy participants will be assessed using MR techniques to assess whether an injection of L-carnitine can lead to increase of L-carnitine in the liver such that it can be detected by MR. This is to validate a methodology prior to using it in NAFLD participants.

Description:

STUDY 1: Functional and Metabolic Parameters in participants with NAFLD Participants will undertake two study visits, within a 14-day period. One of the visits will involve MR assessments that will take up to three hours in total. The second visit will involve a postprandial study day using stable isotopes. Baseline samples will be taken from participants, and after they have been fed a standardised test meal to assess whole-body and liver specific postprandial metabolism - this visit will last up to eight hours. Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS) and stable isotope labelling are two methodologies to investigate in vivo metabolism and function non-invasively. MRI gives information about liver structure and tissue composition, and heart function. MRS can also evaluate tissue energetics and composition using spectroscopy. Stable isotope-labelling studies allow for the measurement of whole-body fatty acid oxidation and de-novo lipogenesis in the pre- and post-prandial state. These two methodologies will be used in our study to evaluate participants with different severity of NAFLD and could help elucidate how the disease progresses. STUDY 2: MRI evaluation of L-carnitine In parallel to study 1, the physiological response to L-carnitine (50 mg/kg i.v.) will be investigated only in healthy participants with 1H MRS. These participants will only take part in one visit, during which they will undergo a baseline MRI scan, followed by the injection of L-carnitine. The MRI/MRS will be repeated two hours after the injection. AC has previously been measured in skeletal muscle using 1H MRS. In this study it will be measured in the septum of the heart and in the liver pre and 2 hours post-injection of 50 mg/kg i.v. of L-carnitine.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 40
• Est. completion date: October 1, 2027
• Est. primary completion date: October 1, 2027
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Aged =18
• In cases where histologic evidence is needed, the pathologist evaluation of a liver biopsy should be obtained within 90 days prior to screening. Participants with simple steatosis
• Liver biopsy that shows features of simple steatosis and no signs of advanced fibrosis or NASH (F3) or cirrhosis (F4). Simple steatosis will be defined as the presence of lipid inclusions in = 5% of hepatocytes without both of lobular inflammation and hepatocyte ballooning. Steatosis with either lobular inflammation or ballooning will be included in this category provided there is no bridging fibrosis (<F3 on the NASH CRN fibrosis classification system), OR
• Findings of fatty liver on ultrasound in patients with low risk of NASH or advanced fibrosis defined as liver stiffness measurement <8kPa. Participants with NASH: o Liver biopsy that shows presence of all the features of NASH (= 5% steatosis, lobular inflammation and hepatocyte ballooning) and without liver cirrhosis. Low-grade fibrosis are allowed.

Participants with NASH cirrhosis:

• Liver biopsy that shows features of NASH cirrhosis. Historical liver biopsies will be acceptable provided there has been no significant weight loss (> 5% of body weight) between the time of biopsy and recruitment, OR
• Presence of metabolic comorbidities and clinical (stigmata of chronic liver disease), radiological (e.g. irregular liver edge, features of portal hypertension), laboratory (deranged clotting, low platelet count) and non-invasive test results consistent with liver cirrhosis (e.g. liver stiffness >20kPa).

Exclusion Criteria:

• The participant may not enter the study if ANY of the following apply:

For the albumin1 infusion: At screening individuals are asked about any allergies and in excluded to the albumin infusion in case of egg allergy. In case of lactose intolerance, milk will be exchanged to a lactosefree non-dairy form.

• Contraindication to MRI
• History of alcoholism or a greater than recommended weekly alcohol intake (14 units per week)
• Liver disease other than NAFLD (chronic viral hepatitis B or C, autoimmune liver disease, primary biliary cholangitis, primary sclerosing cholangitis, haemochromatosis, Wilson's disease, alpha 1 antitrypsin deficiency, drug induced liver injury)
• Pregnant/Planning to get pregnant
• Low haemoglobin (NAFLD participants), women with Hb < 11g/l and men with Hb <12g/l will be excluded
• Unwillingness to refrain from blood donations in the specified period (NAFLD participants)
• Extensive tattooing covering the MRI scanning area

Related Conditions & MeSH terms

• Fatty Liver
• Liver Diseases
• Non-Alcoholic Fatty Liver Disease

Intervention

Diagnostic Test:
• Magnetic Resonance Imaging
Magnetic Resonance Imaging

Other:
• Stable Isotope Study
Stable Isotope study

Locations

Country	Name	City	State
United Kingdom	University of Oxford	Oxford	Oxfordshire

Sponsors (1)

Lead Sponsor	Collaborator
University of Oxford

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Savic D, Mozes FE, Green PG, Burrage MK, Kjaer MS, Hodson L, Neubauer S, Pavlides M, Valkovic L. Detection and alterations of acetylcarnitine (AC) in human liver by 1 H MRS at 3T after supplementation with l-carnitine. Magn Reson Med. 2023 Apr;89(4):1314-1322. doi: 10.1002/mrm.29544. Epub 2022 Dec 27. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Differences in whole-body fatty acid oxidation in a stable isotope labelled postprandial study day in participant groups.	Changes in the incorporation of 13C (from dietary fat or sugar) into CO2 measured using a breath analyser, as a marker of whole-body dietary fatty acid/glucose oxidations.To explore whole-body fatty acid oxidation in individuals with simple steatosis, NASH and NASH with Cirrhosis	baseline
Secondary	Intrahepatic fatty acid synthesis in a stable isotope labelled postprandial study day in participant groups	Differences in hepatic fatty acid synthesis as measured by incorporation of 2H2 palmitate from 2H2O into very low density lipoprotein triglyceride (VLDL-TG) in participants with simple steatosis, NASH and NASH Cirrhosis.	baseline
Secondary	Cardiac Function using MRI in participant groups	Comparison of the cardiac function as assessed by ejection fraction	baseline
Secondary	Difference in liver metabolites using MRS in participant groups	Differences in hepatic energetics using 31P MRS comparing Pi/ATP ratio in participants with simple steatosis, NASH and NASH Cirrhosis.	baseline
Secondary	Difference in heart metabolites using MRS in participant groups	Differences in cardiac fat content using 1H MRS in participants with simple steatosis, NASH and NASH Cirrhosis.	baseline